BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

848 related articles for article (PubMed ID: 26686393)

  • 1. Medicinal chemistry of adenosine, P2Y and P2X receptors.
    Jacobson KA; Müller CE
    Neuropharmacology; 2016 May; 104():31-49. PubMed ID: 26686393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.
    Jacobson KA; Balasubramanian R; Deflorian F; Gao ZG
    Purinergic Signal; 2012 Sep; 8(3):419-36. PubMed ID: 22371149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic potential of purinergic signalling.
    Burnstock G
    Biochem Pharmacol; 2018 May; 151():157-165. PubMed ID: 28735873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration.
    Burnstock G
    Neuropharmacology; 2016 May; 104():4-17. PubMed ID: 26056033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Silico Drug Design for Purinergic GPCRs: Overview on Molecular Dynamics Applied to Adenosine and P2Y Receptors.
    Salmaso V; Jacobson KA
    Biomolecules; 2020 May; 10(6):. PubMed ID: 32466404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets.
    Jacobson KA; IJzerman AP; Müller CE
    Biochem Pharmacol; 2021 May; 187():114311. PubMed ID: 33130128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New paradigms in purinergic receptor ligand discovery.
    Jacobson KA; Pradhan B; Wen Z; Pramanik A
    Neuropharmacology; 2023 Jun; 230():109503. PubMed ID: 36921890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular structure and function of P2X receptors.
    Habermacher C; Dunning K; Chataigneau T; Grutter T
    Neuropharmacology; 2016 May; 104():18-30. PubMed ID: 26231831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Would calcium or potassium channels be responsible for cardiac arrest produced by adenosine and ATP in the right atria of Wistar rats?
    Camara H; Rodrigues JQ; Alves GA; da Silva Junior ED; Caricati-Neto A; Garcia AG; Jurkiewicz A
    Eur J Pharmacol; 2015 Dec; 768():199-206. PubMed ID: 26528795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the Role of N
    Petrelli R; Scortichini M; Kachler S; Boccella S; Cerchia C; Torquati I; Del Bello F; Salvemini D; Novellino E; Luongo L; Maione S; Jacobson KA; Lavecchia A; Klotz KN; Cappellacci L
    J Med Chem; 2017 May; 60(10):4327-4341. PubMed ID: 28447789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology and structure of P2Y receptors.
    von Kügelgen I; Hoffmann K
    Neuropharmacology; 2016 May; 104():50-61. PubMed ID: 26519900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P2X and P2Y nucleotide receptors as targets in cardiovascular disease.
    Kennedy C; Chootip K; Mitchell C; Syed NI; Tengah A
    Future Med Chem; 2013 Mar; 5(4):431-49. PubMed ID: 23495690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purinergic signalling in brain ischemia.
    Pedata F; Dettori I; Coppi E; Melani A; Fusco I; Corradetti R; Pugliese AM
    Neuropharmacology; 2016 May; 104():105-30. PubMed ID: 26581499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.
    Jacobson KA
    J Med Chem; 2013 May; 56(10):3749-67. PubMed ID: 23597047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The P2Y/P2X divide: How it began.
    Kennedy C
    Biochem Pharmacol; 2021 May; 187():114408. PubMed ID: 33444568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms.
    Jespers W; Schiedel AC; Heitman LH; Cooke RM; Kleene L; van Westen GJP; Gloriam DE; Müller CE; Sotelo E; Gutiérrez-de-Terán H
    Trends Pharmacol Sci; 2018 Jan; 39(1):75-89. PubMed ID: 29203139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tools and drugs for uracil nucleotide-activated P2Y receptors.
    Rafehi M; Müller CE
    Pharmacol Ther; 2018 Oct; 190():24-80. PubMed ID: 29660366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. John Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y Receptors.
    Jacobson KA; Gao ZG; Paoletta S; Kiselev E; Chakraborty S; Jayasekara PS; Balasubramanian R; Tosh DK
    Comput Struct Biotechnol J; 2015; 13():286-98. PubMed ID: 25973142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purinergic receptor agonists modulate phagocytosis and clearance of apoptotic cells in macrophages.
    Marques-da-Silva C; Burnstock G; Ojcius DM; Coutinho-Silva R
    Immunobiology; 2011; 216(1-2):1-11. PubMed ID: 20471713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel Adenosine Receptor Antagonists through a Combined Structure- and Ligand-Based Approach Followed by Molecular Dynamics Investigation of Ligand Binding Mode.
    Lagarias P; Vrontaki E; Lambrinidis G; Stamatis D; Convertino M; Ortore G; Mavromoustakos T; Klotz KN; Kolocouris A
    J Chem Inf Model; 2018 Apr; 58(4):794-815. PubMed ID: 29485875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.